Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14441116 | 0.91 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8849456 | 0.84 | MEN1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24290062 | 0.83 | CHRNB2 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5652672 | 0.82 | MEN1 (0.34) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL14446813 | 0.76 | TP53 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8849464 | 0.76 | MEN1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11607376 | 0.75 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL732890 | 0.75 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1162010 | 0.75 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11942479 | 0.75 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | claimed |
| WO-2007081889-A9 | PRODUCTION OF DOLASETRON | TEVA GYOGYSZERGYAR ZARTKORUEN (HU) | 2007-09-20 | — | — | WO | claimed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | claimed |
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | disclosed |
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | disclosed |
| EP-1874767-A2 | PRODUCTION OF DOLASETRON | Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság (HU) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007081889-A9 | PRODUCTION OF DOLASETRON | TEVA GYOGYSZERGYAR ZARTKORUEN (HU) | 2007-09-20 | — | — | WO | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007081889-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203219-A1 | Production of dolasetron | DDOST, DAD1, DHPS | ALDH1A1 2955/4885CYP3A4 31/4885SMN1; SMN2 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.